Tag: Acute Lymphocytic Leukemia (ALL)

Panel Backs CAR T-cell Therapy for Leukemia: What You Need to Know and What’s Next

The US and Drug Administration (FDA) this week convened a panel of outdoor skilleds to weigh in at the readiness of a first-of-its-kind cancer remedy called CAR T-cell thtechnologypy. The panel unanimously counseled that the firm approve the remedy. What does this mean for patients? And is CAR T-cell thtechnologypy going to play an expanding role in cancer remedy in total? In this interview, Leonard Lichtenfeld, MD, MACP, American Cancer Society deputy leader scientific place of workr, gives us his take.

Continue Reading Panel Backs CAR T-cell Therapy for Leukemia: What You Need to Know and What’s Next

FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute Lymphoblastic Leukemia in Adults

The US Food and Drug Administration has licensed the objectiveed thtechnologypy drug Besponsa (ino longeruzumab ozogamicin) for adults with B-cell precursor alovable lymphobultimateic leuropeankemia (ALL) this is no longer getting better with remedy, or got here back atoeser remedy.

Continue Reading FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute Lymphoblastic Leukemia in Adults

FDA Approves CAR T-cell Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)

The US Food and Drug Administration (FDA) has licensed Kymriah (tisagenlecleuropeancel) for certain kidren, adolescents, and young adults with a shape of alovable lymphobultimateic leuropeankemia (ALL).

Continue Reading FDA Approves CAR T-cell Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)

FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute Lymphoblastic Leukemia in Adults

The US Food and Drug Administration has licensed the objectiveed thtechnologypy drug Besponsa (ino longeruzumab ozogamicin) for adults with B-cell precursor alovable lymphobultimateic leuropeankemia (ALL) this is no longer getting better with remedy, or got here back atoeser remedy.

Continue Reading FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute Lymphoblastic Leukemia in Adults